Sometimes it turns out that bigger isn’t better, especially when it comes to compute clusters. “Anything that gives more power in a smaller footprint is good,” said Jeffrey Skolnick of his most recent high-performance computing purchase: an IBM BladeCenter cluster. Skolnick’s previous HPC toy, a 4,000-processor Dell cluster that was christened in 2002 with much fanfare — and a few sound bites from CEO Michael Dell — won’t be thrown in the dumpster just yet, but will be “augmented” by the IBM system, Skolnick said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.